CA2252643A1 - Procedes et compositions pour la regulation de sous-ensembles de lymphocytes t par la modulation de l'activite du facteur de transcription - Google Patents

Procedes et compositions pour la regulation de sous-ensembles de lymphocytes t par la modulation de l'activite du facteur de transcription Download PDF

Info

Publication number
CA2252643A1
CA2252643A1 CA002252643A CA2252643A CA2252643A1 CA 2252643 A1 CA2252643 A1 CA 2252643A1 CA 002252643 A CA002252643 A CA 002252643A CA 2252643 A CA2252643 A CA 2252643A CA 2252643 A1 CA2252643 A1 CA 2252643A1
Authority
CA
Canada
Prior art keywords
protein
nip45
cell
maf
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002252643A
Other languages
English (en)
Inventor
Laurie H. Glimcher
Martin R. Hodge
I-Cheng Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/636,602 external-priority patent/US5958671A/en
Priority claimed from US08/755,584 external-priority patent/US5858711A/en
Priority claimed from US08/755,592 external-priority patent/US6537810B1/en
Application filed by Individual filed Critical Individual
Publication of CA2252643A1 publication Critical patent/CA2252643A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Husbandry (AREA)

Abstract

L'invention concerne des procédés de modulation de la production d'une cytokine associée à un lymphocyte T auxiliaire de type 2 (Th2), en particulier l'interleukine 4, par la modulation de l'activité d'un ou plusieurs facteurs de transcription qui coopèrent avec des protéines de la famille NF-AT pour réguler l'expression d'un gène de cytokine associé à Th2. Dans un mode de réalisation, l'activité d'une protéine de la famille maf (ex. protéine c-Maf ou une petite protéine maf telle que p18) est modulée. Dans un autre mode de réalisation, l'activité d'une protéine interagissant avec une protéine de la famille NF-AT (ex: NIP45) est modulée. L'invention porte également sur des méthodes de combinaison, par exemple dans lesquelles les activités d'une protéine de la famille maf et d'une protéine NF-AT sont modulées ou les activités d'une protéine maf et d'une protéine interagissant avec NF-AT sont modulées. Des procédés de modulation du développement de sous-ensembles de lymphocytes T de type 1 (Th1) ou de type 2 (Th2) chez un sujet, au moyen d'agents qui modulent l'activité du facteur de transcription sont également décrits. Des compositions de NIP45, comprenant des molécules d'acide nucléique isolées codant NIP45, des molécules d'acide nucléique antisens, des vecteurs d'expression de recombinaison contenant une molécule d'acide nucléique NIP 45, des cellules hôtes dans lesquelles lesdits vecteurs d'expression ont été introduits et des animaux transgénique non humains portant un transgène de NIP45 sont également décrits. L'invention se rapporte aussi à des peptides et des protéines NIP45 isolés, des protéines de fusion NIP45 et des anticorps anti-NIP45. Des procédés d'utilisation des compositions de NIP45 selon l'invention sont également décrits.
CA002252643A 1996-04-23 1997-04-23 Procedes et compositions pour la regulation de sous-ensembles de lymphocytes t par la modulation de l'activite du facteur de transcription Abandoned CA2252643A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US08/636,602 US5958671A (en) 1996-04-23 1996-04-23 Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US08/636,602 1996-04-23
US08/755,584 US5858711A (en) 1996-11-25 1996-11-25 NF-AT-interacting protein NIP45 and methods of use therefor
US08/755,592 1996-11-25
US08/755,584 1996-11-25
US08/755,592 US6537810B1 (en) 1996-04-23 1996-11-25 Methods for regulating T cell subsets by modulating transcription factor activity
PCT/US1997/006708 WO1997039721A2 (fr) 1996-04-23 1997-04-23 Procedes et compositions pour la regulation de sous-ensembles de lymphocytes t par la modulation de l'activite du facteur de transcription

Publications (1)

Publication Number Publication Date
CA2252643A1 true CA2252643A1 (fr) 1997-10-30

Family

ID=27417596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002252643A Abandoned CA2252643A1 (fr) 1996-04-23 1997-04-23 Procedes et compositions pour la regulation de sous-ensembles de lymphocytes t par la modulation de l'activite du facteur de transcription

Country Status (8)

Country Link
EP (1) EP0891425A2 (fr)
JP (1) JP2000510333A (fr)
KR (1) KR20000010606A (fr)
CN (1) CN1225682A (fr)
AU (1) AU720455B2 (fr)
CA (1) CA2252643A1 (fr)
NZ (1) NZ332897A (fr)
WO (1) WO1997039721A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722388D0 (en) * 1997-10-24 1997-12-24 Zeneca Ltd NIP45 human homolog
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
AU4219899A (en) 1998-05-28 1999-12-13 President And Fellows Of Harvard College Methods and compositions relating to modulation of cartilage cell growth and/or differentiation by modulation of nfatp activity
WO2001049717A2 (fr) * 1999-12-30 2001-07-12 President And Fellows Of Harvard College Procedes et compositions destines a la modulation de la croissance hepatocyte, a la differenciation du plasmocyte ou a l'activite du sous-ensemble du lymphocyte t par modulation de l'activite du xbp-1
EP1259592A1 (fr) * 2000-01-11 2002-11-27 Maxygen, Inc. Sous-ensembles de cellules dendritiques d riv es de monocytes
DE60123235T2 (de) * 2000-04-25 2007-09-13 Bayer Healthcare Ag Regulation einer nf-at interagierenden proteinvariante nip 45
WO2002029403A1 (fr) * 2000-10-02 2002-04-11 Mochida Pharmaceutical Co., Ltd. Inhibiteur de l'expression de gata-3 et procede de depistage dudit inhibiteur
WO2002069977A1 (fr) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Traitement de déficiences affectant les globules sanguins
US20050079496A1 (en) * 2001-08-17 2005-04-14 Edgar Serfling Methods for diagnosing and treating neoplasias using nf-at transcriptions factors
IL147138A0 (en) 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
AU2007220300A1 (en) * 2006-03-02 2007-09-07 Antitope Limited T cell assays
US8227184B2 (en) 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
KR101146335B1 (ko) * 2009-10-12 2012-05-21 한국원자력의학원 알파태아단백 인헨서 및 프로모터의 조절을 받아 리포터 단백질을 발현하는 형질 전환 마우스, 그의 제조 방법 및 이를 이용한 알파태아단백 발현의 증가 또는 감소 유도 물질을 스크리닝하는 방법
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
WO2015019125A1 (fr) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Cibles moléculaires destinées au traitement des blessures, en particulier des blessures chroniques
WO2015048331A1 (fr) 2013-09-25 2015-04-02 Cornell University Composés pour induire une immunité anti-tumorale et procédés associés

Also Published As

Publication number Publication date
CN1225682A (zh) 1999-08-11
JP2000510333A (ja) 2000-08-15
AU3115597A (en) 1997-11-12
WO1997039721A2 (fr) 1997-10-30
AU720455B2 (en) 2000-06-01
KR20000010606A (ko) 2000-02-15
EP0891425A2 (fr) 1999-01-20
NZ332897A (en) 2000-04-28
WO1997039721A3 (fr) 1998-04-09

Similar Documents

Publication Publication Date Title
US20070009918A1 (en) Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US6933125B2 (en) Human c-Maf compositions and methods of use thereof
AU720455B2 (en) Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US7745581B2 (en) T-bet compositions and methods of use thereof
JP2010011856A (ja) Ｔ−ｂｅｔ組成物およびその使用の方法
US20030186377A1 (en) T-bet compositions and methods of use thereof
US5858711A (en) NF-AT-interacting protein NIP45 and methods of use therefor
US6537810B1 (en) Methods for regulating T cell subsets by modulating transcription factor activity
AU2006201827B2 (en) T-bet compositions and methods of use thereof
AU775862B2 (en) Human c-Maf compositions and methods of use thereof
WO1998011209A1 (fr) Compositions a skap55 et leurs procedes d'utilisation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead